Moreover, treating CKD rats with β,γ-meATP or MDP prevented the upregulation of the osteo-/chondrogenic marker Sox9, indicating that both compounds affect osteogenic conversion of VSMCs. Here, SOX9 is linked to chronic kidney disease.